| Methods |
Randomized, double‐blind, controlled, prospective clinical study |
| Participants |
Inpatients less than 18 months old admitted with acute bronchiolitis. No underlying lung/cardiac disease
Country: Australia |
| Interventions |
2 doses (with 2‐hour interval) of nebulized ipratropium bromide 1 ml (250 µg) in 4 ml saline or 5 ml saline placebo |
| Outcomes |
Oxygen saturation, RACS, respiratory rate, heart rate |
| Notes |
— |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
High risk |
Not described |
| Allocation concealment (selection bias) |
Low risk |
|
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
|
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
|
| Selective reporting (reporting bias) |
Low risk |
|
